Electric pulses could zap lung tumors without surgery

NCT ID NCT06739031

Recruiting now Disease control Sponsor: Energenx Medical LTD. Source: ClinicalTrials.gov ↗

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial is testing whether a device that uses pulsed electric fields (PEF) can safely and effectively destroy early-stage non-small cell lung cancer tumors in people who are not candidates for surgery. The study will measure how completely the tumors are ablated at six months, as well as survival and quality of life. Participants will receive the PEF ablation procedure and be followed for a year to assess outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pulsed electric field (PEF) ablation device
What this could lead to: If successful, this could offer a new, less invasive treatment option for people with early-stage lung cancer who cannot have surgery, potentially improving local control and survival.
What could go wrong: This is an early-stage trial, so the treatment may not be effective for everyone or may have unexpected side effects. The long-term benefits and risks are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine,
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.